umbilical vein ec Search Results


99
PromoCell human umbilical vein endothelial cells
Human Umbilical Vein Endothelial Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human umbilical vein endothelial cells/product/PromoCell
Average 99 stars, based on 1 article reviews
human umbilical vein endothelial cells - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

90
Cambrex human umbilical cord vein ec
Human Umbilical Cord Vein Ec, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human umbilical cord vein ec/product/Cambrex
Average 90 stars, based on 1 article reviews
human umbilical cord vein ec - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Genentech inc human umbilical vein ec cdna library in lgtll
Human Umbilical Vein Ec Cdna Library In Lgtll, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human umbilical vein ec cdna library in lgtll/product/Genentech inc
Average 90 stars, based on 1 article reviews
human umbilical vein ec cdna library in lgtll - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
ScienCell ec cells (human umbilical vein endothelial cells)
Ec Cells (Human Umbilical Vein Endothelial Cells), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ec cells (human umbilical vein endothelial cells)/product/ScienCell
Average 90 stars, based on 1 article reviews
ec cells (human umbilical vein endothelial cells) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Cambrex human microvascular and umbilical vein ec
Human Microvascular And Umbilical Vein Ec, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human microvascular and umbilical vein ec/product/Cambrex
Average 90 stars, based on 1 article reviews
human microvascular and umbilical vein ec - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
HiMedia Laboratories huvec #cl002-2xt25
Intermittent high glucose imparts mesenchymal character <t>in</t> <t>endothelial</t> cells both in vitro and in vivo . (A , B) Immunoblot analysis of <t>HUVEC</t> lysates collected from cells treated with differential high-glucose treatment conditions and probed for α-SMA ( A , n = 3), Slug ( A , n = 5), CD144 ( A , n = 5), and CD31 ( B , n = 5) along with their respective densitometry quantification analysis. (C) Immunofluorescence analysis and costaining of HUVEC exposed to intermittent high glucose for α-SMA and CD144. DAPI staining to visualize the nucleus is shown in blue ( n = 3). (D) Immunohistochemistry of tissue sections from BTBR WT and BTBR Ob/Ob mice stained for α-SMA and CD31 ( n = 3). DAPI staining is shown in blue. Images were acquired with Zeiss LSM 780 Microscope. White arrowheads indicate endothelial cells expressing both CD31 and α-SMA. Degree of colocalization was analyzed using the Coloc2 plugin of ImageJ and Pearson correlation coefficient values were plotted to indicate the level of colocalization between CD31 and α-SMA. Values represent the mean ± SD. ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.
Huvec #Cl002 2xt25, supplied by HiMedia Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/huvec #cl002-2xt25/product/HiMedia Laboratories
Average 90 stars, based on 1 article reviews
huvec #cl002-2xt25 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Intermittent high glucose imparts mesenchymal character in endothelial cells both in vitro and in vivo . (A , B) Immunoblot analysis of HUVEC lysates collected from cells treated with differential high-glucose treatment conditions and probed for α-SMA ( A , n = 3), Slug ( A , n = 5), CD144 ( A , n = 5), and CD31 ( B , n = 5) along with their respective densitometry quantification analysis. (C) Immunofluorescence analysis and costaining of HUVEC exposed to intermittent high glucose for α-SMA and CD144. DAPI staining to visualize the nucleus is shown in blue ( n = 3). (D) Immunohistochemistry of tissue sections from BTBR WT and BTBR Ob/Ob mice stained for α-SMA and CD31 ( n = 3). DAPI staining is shown in blue. Images were acquired with Zeiss LSM 780 Microscope. White arrowheads indicate endothelial cells expressing both CD31 and α-SMA. Degree of colocalization was analyzed using the Coloc2 plugin of ImageJ and Pearson correlation coefficient values were plotted to indicate the level of colocalization between CD31 and α-SMA. Values represent the mean ± SD. ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Elevated H3K4me3 Through MLL2-WDR82 upon Hyperglycemia Causes Jagged Ligand Dependent Notch Activation to Interplay with Differentiation State of Endothelial Cells

doi: 10.3389/fcell.2022.839109

Figure Lengend Snippet: Intermittent high glucose imparts mesenchymal character in endothelial cells both in vitro and in vivo . (A , B) Immunoblot analysis of HUVEC lysates collected from cells treated with differential high-glucose treatment conditions and probed for α-SMA ( A , n = 3), Slug ( A , n = 5), CD144 ( A , n = 5), and CD31 ( B , n = 5) along with their respective densitometry quantification analysis. (C) Immunofluorescence analysis and costaining of HUVEC exposed to intermittent high glucose for α-SMA and CD144. DAPI staining to visualize the nucleus is shown in blue ( n = 3). (D) Immunohistochemistry of tissue sections from BTBR WT and BTBR Ob/Ob mice stained for α-SMA and CD31 ( n = 3). DAPI staining is shown in blue. Images were acquired with Zeiss LSM 780 Microscope. White arrowheads indicate endothelial cells expressing both CD31 and α-SMA. Degree of colocalization was analyzed using the Coloc2 plugin of ImageJ and Pearson correlation coefficient values were plotted to indicate the level of colocalization between CD31 and α-SMA. Values represent the mean ± SD. ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.

Article Snippet: HUVEC (#CL002-2XT25, Himedia) were cultured in HiEndoXL TM Endothelial Cell Expansion medium (#AL517; Himedia) supplemented with 4% endothelial growth supplement, 3% fetal bovine serum (#RM1112, FBS; Himedia), and 1X penicillin streptomycin glutamine (#10378, PS; Gibco).

Techniques: In Vitro, In Vivo, Western Blot, Immunofluorescence, Staining, Immunohistochemistry, Microscopy, Expressing

Intermittent hyperglycemia caused increased levels of H3K4me3 through upregulation of MLL2 and WDR82. (A – F) Immunoblot analysis of HUVEC lysates collected from cells treated with differential/intermittent high-glucose treatment conditions and probed for H3K4me3 ( A , n = 7), MLL2 ( B , n = 6), WDR82 ( C , n = 5), SET1A ( D , n = 5), MLL1 (CT) ( D , n = 6), Menin ( D , n = 3), WDR5 ( D , n = 6), SET1B ( E , n = 3), and MLL1 (NT) ( F , n = 3). (G) Immunohistochemistry of tissue sections from control and Ob/Ob mice stained for H3K4me3 and CD31 ( n = 6). Fluorescence intensity AU values per individual cell nucleus are indicated together with the mean. Total number of nuclei, n ≥ 150. (H , I) Immunoblotting for H3K4me3 (H) , WDR82 (H), and MLL2 (I) in cultured HUVEC exposed to intermittent high glucose with a high-glucose concentration of 15 and 25 mM ( n = 3). (J – L) Immunoblot analysis of rat aorta tissue lysates collected from cells treated with intermittent high-glucose treatment conditions and probed for H3K4me3 (J) , MLL2 (K) and WDR82 (L) along with their respective densitometry quantification. Values represent the mean ± SD. * p < .05, ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Elevated H3K4me3 Through MLL2-WDR82 upon Hyperglycemia Causes Jagged Ligand Dependent Notch Activation to Interplay with Differentiation State of Endothelial Cells

doi: 10.3389/fcell.2022.839109

Figure Lengend Snippet: Intermittent hyperglycemia caused increased levels of H3K4me3 through upregulation of MLL2 and WDR82. (A – F) Immunoblot analysis of HUVEC lysates collected from cells treated with differential/intermittent high-glucose treatment conditions and probed for H3K4me3 ( A , n = 7), MLL2 ( B , n = 6), WDR82 ( C , n = 5), SET1A ( D , n = 5), MLL1 (CT) ( D , n = 6), Menin ( D , n = 3), WDR5 ( D , n = 6), SET1B ( E , n = 3), and MLL1 (NT) ( F , n = 3). (G) Immunohistochemistry of tissue sections from control and Ob/Ob mice stained for H3K4me3 and CD31 ( n = 6). Fluorescence intensity AU values per individual cell nucleus are indicated together with the mean. Total number of nuclei, n ≥ 150. (H , I) Immunoblotting for H3K4me3 (H) , WDR82 (H), and MLL2 (I) in cultured HUVEC exposed to intermittent high glucose with a high-glucose concentration of 15 and 25 mM ( n = 3). (J – L) Immunoblot analysis of rat aorta tissue lysates collected from cells treated with intermittent high-glucose treatment conditions and probed for H3K4me3 (J) , MLL2 (K) and WDR82 (L) along with their respective densitometry quantification. Values represent the mean ± SD. * p < .05, ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.

Article Snippet: HUVEC (#CL002-2XT25, Himedia) were cultured in HiEndoXL TM Endothelial Cell Expansion medium (#AL517; Himedia) supplemented with 4% endothelial growth supplement, 3% fetal bovine serum (#RM1112, FBS; Himedia), and 1X penicillin streptomycin glutamine (#10378, PS; Gibco).

Techniques: Western Blot, Immunohistochemistry, Control, Staining, Fluorescence, Cell Culture, Concentration Assay

Elevated H3K4me3 upon intermittent high-glucose exposure enriched in Jagged1 and Jagged2 promoter, thereby causing their expression and Notch activation in endothelial cells. (A , B) Immunoblot analysis of endothelial cell lysates collected from cells treated with intermittent, transient, and constant high glucose and probed for N1-ICD ( A , n = 3) and Hes1 ( B , n = 3). (C , D) ChIP-qPCR analysis of H3K4me3 enrichment on Jagged1 ( C , n = 4) and Jagged2 ( D , n = 3) gene promoters in HUVEC exposed to intermittent hyperglycemia. (E , F) Transcript-level expression of Jagged1 ( E , n = 4) and Jagged2 ( F , n = 4) measured through RT-qPCR technique in HUVEC challenged with an intermittent high-glucose condition. (G , H) Immunoblot analysis of HUVEC lysates collected from cells treated with differential high-glucose treatment conditions and probed for Jagged1 ( G , n = 5) and Jagged2 ( H , n = 4). (I , J) Human glomerular endothelial cells (HGMEC) were treated with intermittent high-glucose treatment conditions and immunoblotted for Jagged1 ( I , n = 3) and Jagged2 ( G , n = 3). (K – M) Immunoblot analysis of rat aorta tissue lysates collected from cells treated with intermittent high-glucose treatment conditions and probed for N1-ICD ( K , n = 3) Jagged1 ( L , n = 3), Jagged2 ( M , n = 3). Values represent the mean ± SD. * p < .05, ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Elevated H3K4me3 Through MLL2-WDR82 upon Hyperglycemia Causes Jagged Ligand Dependent Notch Activation to Interplay with Differentiation State of Endothelial Cells

doi: 10.3389/fcell.2022.839109

Figure Lengend Snippet: Elevated H3K4me3 upon intermittent high-glucose exposure enriched in Jagged1 and Jagged2 promoter, thereby causing their expression and Notch activation in endothelial cells. (A , B) Immunoblot analysis of endothelial cell lysates collected from cells treated with intermittent, transient, and constant high glucose and probed for N1-ICD ( A , n = 3) and Hes1 ( B , n = 3). (C , D) ChIP-qPCR analysis of H3K4me3 enrichment on Jagged1 ( C , n = 4) and Jagged2 ( D , n = 3) gene promoters in HUVEC exposed to intermittent hyperglycemia. (E , F) Transcript-level expression of Jagged1 ( E , n = 4) and Jagged2 ( F , n = 4) measured through RT-qPCR technique in HUVEC challenged with an intermittent high-glucose condition. (G , H) Immunoblot analysis of HUVEC lysates collected from cells treated with differential high-glucose treatment conditions and probed for Jagged1 ( G , n = 5) and Jagged2 ( H , n = 4). (I , J) Human glomerular endothelial cells (HGMEC) were treated with intermittent high-glucose treatment conditions and immunoblotted for Jagged1 ( I , n = 3) and Jagged2 ( G , n = 3). (K – M) Immunoblot analysis of rat aorta tissue lysates collected from cells treated with intermittent high-glucose treatment conditions and probed for N1-ICD ( K , n = 3) Jagged1 ( L , n = 3), Jagged2 ( M , n = 3). Values represent the mean ± SD. * p < .05, ** p < .01, and *** p < .001, either by unpaired t -test for two groups or the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test for comparisons of multiple groups.

Article Snippet: HUVEC (#CL002-2XT25, Himedia) were cultured in HiEndoXL TM Endothelial Cell Expansion medium (#AL517; Himedia) supplemented with 4% endothelial growth supplement, 3% fetal bovine serum (#RM1112, FBS; Himedia), and 1X penicillin streptomycin glutamine (#10378, PS; Gibco).

Techniques: Expressing, Activation Assay, Western Blot, ChIP-qPCR, Quantitative RT-PCR

Catalytic inhibition or siRNA-mediated knockdown of MLL blocked intermittent high-glucose-dependent mesenchymal switch of endothelial cells. (A) HUVEC were exposed to intermittent high-glucose treatment condition in combination with OICR-9429 and incubated for a total of 5 days followed by immunoblot analysis by probing for α-SMA and Slug along with densitometry quantification of the blots ( n = 4). (B) HUVEC were transfected with MLL2 specific siRNA followed by challenging with intermittent high glucose and incubation for a total of 5 days. Resultant cell lysate was immunoblotted and probed for α-SMA and Slug along with densitometry quantification of the blots ( n = 4). Values represent the mean ± SD. ** p < .01, and *** p < .001, by the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Elevated H3K4me3 Through MLL2-WDR82 upon Hyperglycemia Causes Jagged Ligand Dependent Notch Activation to Interplay with Differentiation State of Endothelial Cells

doi: 10.3389/fcell.2022.839109

Figure Lengend Snippet: Catalytic inhibition or siRNA-mediated knockdown of MLL blocked intermittent high-glucose-dependent mesenchymal switch of endothelial cells. (A) HUVEC were exposed to intermittent high-glucose treatment condition in combination with OICR-9429 and incubated for a total of 5 days followed by immunoblot analysis by probing for α-SMA and Slug along with densitometry quantification of the blots ( n = 4). (B) HUVEC were transfected with MLL2 specific siRNA followed by challenging with intermittent high glucose and incubation for a total of 5 days. Resultant cell lysate was immunoblotted and probed for α-SMA and Slug along with densitometry quantification of the blots ( n = 4). Values represent the mean ± SD. ** p < .01, and *** p < .001, by the two-stage linear step-up procedure of Benjamin, Krieger, and Yekutieli test.

Article Snippet: HUVEC (#CL002-2XT25, Himedia) were cultured in HiEndoXL TM Endothelial Cell Expansion medium (#AL517; Himedia) supplemented with 4% endothelial growth supplement, 3% fetal bovine serum (#RM1112, FBS; Himedia), and 1X penicillin streptomycin glutamine (#10378, PS; Gibco).

Techniques: Inhibition, Knockdown, Incubation, Western Blot, Transfection